REGENEREX PHARMA, INC. Operating Income Loss

• REGENEREX PHARMA, INC. showed an increase of +47.3% in Operating Income Loss from 2024 to 2025.
• This data is from REGENEREX PHARMA, INC.'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), REGENEREX PHARMA, INC.'s Operating Income Loss has declined by 70,871.5%.
• Historical annual values: Fiscal year 2025: -$1.83 million | Fiscal year 2024: -$3.47 million | Fiscal year 2023: -$96.2 thousand | Fiscal year 2022: -$126.3 thousand | Fiscal year 2021: -$43.4 thousand | Fiscal year 2020: -$77.0 thousand | Fiscal year 2019: -$91.7 thousand | Fiscal year 2018: -$49.5 thousand | Fiscal year 2017: -$2.6 thousand.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026